# Mariposa Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mariposa-therapeutics

- Industry: Biotechnology
- Headquarters: UK
- Website: www.mariposa.health/
- Total disclosed funding: $1M
- Latest round: Seed (Mar 12, 2026)
- Investors on record: 1

## About

Based in the UK, Mariposa Therapeutics Limited specializes in innovative treatments for keratin-related skin disorders, focusing on conditions like Epidermolysis Bullosa Simplex and psoriasis, with a commitment to addressing unmet medical needs.Mariposa Therapeutics Limited, founded in 2019 in Cardiff, UK, is dedicated to developing therapeutic solutions for keratin-related disorders. The company has completed 1 funding deal and raised a total amount of GBP 750,000, with the latest round being a SEED funding in March 2026, led by the Development Bank of Wales.Mariposa Therapeutics focuses on developing innovative treatment solutions specifically for keratin-related skin disorders, with particular emphasis on conditions like Epidermolysis Bullosa Simplex and psoriasis. Their core offerings are designed to target and repair the underlying biological mechanisms associated with these disorders, leveraging specialist expertise in epithelial cell biology and keratin intermediate filaments. The company aims to address unmet medical needs for patients suffering from these conditions, providing them with hope for effective treatment options where none currently exist. Mariposa's products are primarily aimed at healthcare providers and patients in the United Kingdom and Europe, given the company's base in Cardiff and its engagement with local and international research organizations.Mariposa Therapeutics generates revenue through partnerships and collaborations with research institutions and healthcare organizations, facilitating the development and potential commercialization of their therapeutic solutions. The company’s revenue model includes agreements for research funding, milestone payments tied to development progress, and potential royalties from product sales upon successful market entry. As the firm advances its flagship treatments for keratin-related disorders, the structure of these transactions is expected to involve collaboration with healthcare providers and possibly licensing agreements to ensure broad distribution.In March 2026, Mariposa Therapeutics secured GBP 750,000 in venture funding led by the Development Bank of Wales, with participation from DEBRA Research GmbH and the company's management. The funding will be utilized for the pre-clinical development of MP5219, supporting further studies, and securing scientific advice and early engagement with regulators. The company is focused on advancing its product pipeline and is considering expansion into additional European markets by 2027.

## Funding rounds

- Seed, Mar 12, 2026, $1M — Development Bank of Wales

## Investors

- Development Bank of Wales (https://capitalatlas.ai/funds/development-bank-of-wales) — Seed